Search results for "Alkylating"

showing 6 items of 66 documents

Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study

2005

Introduction: The primary tumour type most likely to metastasize to the brain is lung cancer. In heavily pre-treated patients, limited therapeutic option is available and the results of availability therapies reported in literature are disappointing. The present phase II study was designed to assess the efficacy and safety of temozolomide (TMZ) as palliative treatment for brain metastases (BrM) in NSCLC patients pre-treated with WBRT and at least one line of chemotherapy for metastatic brain disease. Material and methods: Temozolomide was administered orally at 150 mg/mq/day for five consecutive days for the first cycle, doses were increased to 200 mg/mq/day for 5 days every 28 days for sub…

Pulmonary and Respiratory MedicineOncologyMaleCancer Researchmedicine.medical_specialtyPalliative careLung NeoplasmsBrain metastasemedicine.medical_treatmentPhases of clinical researchAdministration OralPre-treatedInternal medicineCarcinoma Non-Small-Cell LungmedicineCarcinomaTemozolomideHumansAdverse effectLung cancerAntineoplastic Agents AlkylatingAgedChemotherapyTemozolomidebusiness.industryBrain NeoplasmsPalliative CareMiddle Agedmedicine.diseaseSurgeryDacarbazineTreatment OutcomeOncologyFemaleLung cancerbusinessProgressive diseasemedicine.drug
researchProduct

Is the repair of oxidative DNA base modifications inducible by a preceding DNA damage induction?

2007

In mammalian cells, 7,8-dihydro-8-oxoguanine (8-oxoG) and some other oxidative guanine modifications are removed from the DNA by base excision repair, which is initiated by OGG1 protein. We have tested whether this repair is inducible in mouse embryonic fibroblasts (MEFs), MCF-7 breast cancer cells and primary human fibroblasts by a pretreatment with the photosensitizer Ro19-8022 plus light, which generates predominantly 8-oxoG, or with methyl methanesulfonate (MMS), which generates alkylated bases and abasic sites (AP sites). The results indicate that the repair rate of the oxidative guanine modifications induced by the photosensitizer was not increased if a priming dose of the oxidative o…

PyrrolidinesTime FactorsDNA RepairDNA repairGuanineDNA damageBiologymedicine.disease_causeBiochemistryMicechemistry.chemical_compoundTumor Cells CulturedmedicineAnimalsHumansheterocyclic compoundsAntineoplastic Agents AlkylatingBase PairingMolecular BiologyPhotosensitizing AgentsGuanosineDNACell BiologyBase excision repairGlutathioneFibroblastsMethyl MethanesulfonateGlutathioneMolecular biologyMethyl methanesulfonateOxidative StresschemistryFemaleOxidation-ReductionQuinolizinesDNAOxidative stressDNA DamageDNA Repair
researchProduct

Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.

2013

International audience; Dacarbazine (DTIC) is a cytotoxic drug widely used for melanoma treatment. However, the putative contribution of anticancer immune responses in the efficacy of DTIC has not been evaluated. By testing how DTIC affects host immune responses to cancer in a mouse model of melanoma, we unexpectedly found that both natural killer (NK) and CD8(+) T cells were indispensable for DTIC therapeutic effect. Although DTIC did not directly affect immune cells, it triggered the upregulation of NKG2D ligands on tumor cells, leading to NK cell activation and IFNγ secretion in mice and humans. NK cell-derived IFNγ subsequently favored upregulation of major histocompatibility complex cl…

Skin NeoplasmsMelanoma ExperimentalCD8-Positive T-LymphocytesPharmacologyMESH: Antineoplastic Agents AlkylatingLigandsBiochemistryMiceInterleukin 210302 clinical medicineMESH: Up-RegulationMESH: LigandsCytotoxic T cell[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH: AnimalsMESH : Up-RegulationMESH : LigandsMESH : Melanoma ExperimentalMelanomaMESH : Mice NudeMESH : CD8-Positive T-LymphocytesMESH: CD8-Positive T-LymphocytesUp-Regulation3. Good healthDacarbazineKiller Cells NaturalMESH: Melanoma ExperimentalNK Cell Lectin-Like Receptor Subfamily K030220 oncology & carcinogenesisMESH: NK Cell Lectin-Like Receptor Subfamily K[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH : Killer Cells Naturalmedicine.drugMESH: Killer Cells NaturalMESH: Cell Line Tumor[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH: Interferon-gammaDacarbazineMESH : Antineoplastic Agents AlkylatingMice NudeMESH : Mice Inbred C57BLDermatologyBiologyMajor histocompatibility complexMESH: DacarbazineInterferon-gamma03 medical and health sciencesImmune systemDownregulation and upregulationMESH: Mice Inbred C57BLCell Line TumorMESH : MicemedicineMESH : NK Cell Lectin-Like Receptor Subfamily KMESH: Mice NudeAnimalsHumansMESH : DacarbazineAntineoplastic Agents AlkylatingMolecular BiologyMESH: MiceMESH : Interferon-gammaMESH: HumansMESH : Cell Line TumorMESH: Skin NeoplasmsMESH : Skin NeoplasmsMESH : HumansCell Biologymedicine.diseaseMESH : Disease Models AnimalMice Inbred C57BLDisease Models Animalbiology.proteinMESH : AnimalsMESH: Disease Models AnimalCD8030215 immunology
researchProduct

Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis

2010

A genetic basis of hepatocellular carcinoma (HCC) has been well-established and major signaling pathways, such as p53, Wnt-signaling, transforming growth factor-β (TGF-β) and Ras pathways, have been identified to be essential to HCC development. Lately, the family of platelet-derived growth factors (PDGFs) has shifted to the center of interest. We have reported on spontaneously developing liver fibrosis in PDGF-B transgenic mice. Since HCC rarely occurs in healthy liver, but dramatically increases at the cirrhosis stage of which liver fibrosis is a preliminary stage, we investigated liver cancer development in chemically induced liver carcinogenesis in these mice. HCC induction was performe…

Vascular Endothelial Growth Factor AAlkylating AgentsCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularCirrhosisPlatelet-derived growth factorBlotting WesternMice TransgenicBiologymedicine.disease_causeImmunoenzyme TechniquesMicechemistry.chemical_compoundLiver Neoplasms ExperimentalInternal medicinemedicineAnimalsHumansDiethylnitrosamineRNA MessengerReverse Transcriptase Polymerase Chain ReactionCancerProto-Oncogene Proteins c-sismedicine.diseaseFibroblast Growth FactorsPlatelet Endothelial Cell Adhesion Molecule-1Vascular endothelial growth factorEndocrinologyOncologychemistryPhenobarbitalbiology.proteinAnticonvulsantsCarcinogenesisLiver cancerPlatelet-derived growth factor receptorTransforming growth factorInternational Journal of Cancer
researchProduct

Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia

2014

Oral administration of low-dose cyclophosphamide in pets with spontaneously occurring malignant neoplasms has become a common practice in veterinary medicine. The purpose of this retrospective study was to investigate toxicity events in cats with spontaneous malignancies receiving cyclophosphamide as a metronomic therapy for at least 1 month. The number and severity of clinical, haematological and biochemical adverse events were recorded according to the Veterinary Cooperative Oncology Group’s Common Terminology Criteria for Adverse Events v1.1 classification scheme. Twenty-four cats were enrolled in the study with a total number of 27 neoplasms: 13 sarcomas, 12 carcinomas, one melanoma an…

medicine.medical_specialtyToceranibCyclophosphamideCat DiseasesGastroenterologyDisease-Free SurvivalDrug Administration ScheduleMetastasisNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsSmall AnimalsAdverse effectAntineoplastic Agents AlkylatingCyclophosphamideNeoplasm StagingRetrospective StudiesCATSDose-Response Relationship Drugbusiness.industryCommon Terminology Criteria for Adverse Eventsmedicine.diseaseSurgeryThalidomideToxicityCatsbusinessmedicine.drugJournal of Feline Medicine and Surgery
researchProduct

Glutathione, GlutathioneS-Transferase α and π, and Aldehyde Dehydrogenase Content in Relationship to Drug Resistance in Ovarian Cancer

1997

Glutathione, glutathione S-transferases alpha and pi, and aldehyde dehydrogenase are associated with resistance to carboplatin and/or cyclophosphamide in cell lines. Therefore, we examined whether the expression of these factors in ovarian cancer tissue specimens is associated with resistance of the patients to combination chemotherapy with cyclophosphamide/carboplatin. Ovarian cancer tissue specimens were taken intraoperatively from 139 patients and frozen in liquid nitrogen, and the contents of glutathione S-transferases alpha and pi, total glutathione, and aldehyde dehydrogenase activity were determined. No association between the levels of glutathione S-transferases alpha and pi or alde…

medicine.medical_specialtyendocrine system diseasesCyclophosphamidemedicine.medical_treatmentBlotting WesternAldehyde dehydrogenaseAntineoplastic AgentsOvaryCarboplatinchemistry.chemical_compoundInternal medicineHumansMedicineAntineoplastic Agents AlkylatingCyclophosphamideGlutathione TransferaseNeoplasm StagingOvarian NeoplasmsChemotherapybiologybusiness.industryObstetrics and GynecologyCombination chemotherapyGlutathioneAldehyde DehydrogenasePrognosismedicine.diseaseCombined Modality TherapyGlutathioneDrug Resistance Multiplefemale genital diseases and pregnancy complicationsCarboplatinmedicine.anatomical_structureEndocrinologyOncologychemistryDrug Resistance Neoplasmbiology.proteinCancer researchDrug Therapy CombinationFemaleCisplatinbusinessOvarian cancermedicine.drugGynecologic Oncology
researchProduct